.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,741,524

« Back to Dashboard

Details for Patent: 5,741,524

Title: Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
Abstract:Sustained release formulations include an augmented microcrystalline cellulose, an active agent, and a sustained release carrier and methods for making same are disclosed.
Inventor(s): Staniforth; John N. (Bath, GB2), Sherwood; Bob E. (Amenia, NY), Hunter; Edward A. (Glenham, NY)
Assignee: Edward Mendell Co., Inc. (Patterson, NY)
Filing Date:Jul 08, 1996
Application Number:08/676,654
Claims:1. A sustained-release formulation comprising:

an active agent;

an augmented microcrystalline cellulose comprising agglomerated particles of microcrystalline cellulose and a compressibility augmenting agent which

(i) physically restricts the proximity of the interface between adjacent cellulose surfaces, (ii) inhibits interactions between adjacent cellulose surfaces; or (iii) accomplishes both (i) and (ii) above; and a matrix comprising a sustained-release carrier to promote sustained-release of said active agent.

2. The sustained-release formulation of claim 1, wherein said compressibility augmenting agent is a surfactant having an HLB of at least about 10.

3. The sustained-release formulation of claim 1, wherein said compressibility augmenting agent is a surfactant having an HLB of from about 15 to about 40.

4. The sustained release formulation of claim 1, wherein said compressibility augmenting agent is a silicon dioxide derived from a silicon dioxide having an average primary particle size from about 1 nm to about 100 nm.

5. The sustained-release formulation of claim 1, wherein said silicon dioxide is included in an amount from about 0.1% to about 20% by weight, based on the weight of microcrystalline cellulose.

6. The sustained release formulation of claim 4, wherein said silicon dioxide is colloidal silicon dioxide.

7. The sustained-release formulation of claim 1, wherein said compressibility augmenting agent is a surfactant.

8. The sustained-release formulation of claim 7, wherein said compressibility augmenting agent is sodium lauryl sulfate.

9. The sustained release formulation of claim 1, wherein said compressibility augmenting agent is a polysorbate.

10. The sustained-release formulation of claim 2, wherein said surfactant is included in an amount from about 0.1% to about 20% by weight, based on the weight of microcrystalline cellulose.

11. The sustained-release formulation of claim 1, wherein said compressibility augmenting agent is a pharmaceutically acceptable highly polar compound.

12. The sustained-release formulation of claim 11, wherein said highly polar compound is a suitable dye selected from the group consisting of 3,3'-[[1,1'Biphenyl]-4,4'-diylbis-(azo)]bis[4-amino-1-naphthalenesulfonic acid]disodium salt; disodium salt of 6-hydroxy-5[(2-methyl-4-sulfophenyl)azo]-2-naphthalenesulfonic acid); 5-oxo-1-(p-sulfophenyl)-4-[(p-sulfophenyl)azo]-2-pyrazoline-3-carboxylic acid, trisodium salt); disodium salt of 1-p-sulphophenylazo-2-naphthol-6-sulfonic acid); trisodium-2-hydroxy-1-(4-sulfonato-1-naphthylazo)naphthalene-6,8-disulfona te); disodium 4,4'-(2,4-dihydroxy-5-hydroxymethyl-3,3-phenylene bisazo)di(napthalene-1-sulfonate)); tetrasodium 4-acetamido-5-hyroxy-6-[7-sulfonato-4-(4-sulfonatophenylazo)-1-naphthylazo ]naphthalene-1,7-disulfonate); disodium 4-hydroxy-3-(4-sulfanato-1-naphythylazo) Naphthalene-1-sulfonate); trisodium 2-hydroxy-1-(4-sulfonato-1-naphthylazo)naphthalene-3,6-disulfonate); and mixtures thereof.

13. The sustained-release formulation of claim 1, wherein said sustained-release carrier comprises a retardant selected from the group consisting of alkylcelluloses, acrylic and methacrylic acid polymers and copolymers, polylactides, polyglycolides, cellulose ethers, cellulose esters, polyanhydrides, polyorthoesters, polycaprolactones, polyphosphazenes, polysaccharides, proteinaceous polymers, polypeptides, polyesters, polyorthoesters, hydrophilic polymers, hydrophilic gums, waxes and wax-like materials, and mixtures thereof.

14. The sustained-release formulation of claim 13, wherein said retardant is a hydrophilic gum.

15. The sustained-release formulation of claim 13, wherein said retardant is a hydrophilic polymer.

16. The sustained-release formulation of claim 13, which comprises

an immediate release core comprising an augmented microcrystalline cellulose comprising a compressibility augmenting agent, and an effective amount of a therapeutic agent; said core coated with at least a portion of solid sustained released carrier.

17. The sustained-release formulation of claim 16, wherein said immediate release core is in the form of a tablet.

18. The sustained-release formulation of claim 13, which comprises a matrix including said augmented microcrystalline cellulose, at least a portion of said sustained release carrier, and said active agent.

19. The sustained-release formulation of claim 18, wherein said matrix is compressed into a tablet.

20. The sustained-release formulation of claim 19, wherein a portion of said sustained-release carrier is coated onto the surface of said tablet.

21. The sustained-release formulation of claim 18, wherein said highly polar compound is a suitable dye selected from the group consisting of 3,3'-[[1,1'Biphenyl]-4,4'-diylbis-(azo)]bis[4-amino-1-naphthalenesulfonic acid]disodium salt; disodium salt of 6-hydroxy-5[(2-methyl-4-sulfophenyl)azo]-2-naphthalenesulfonic acid); 5-oxo-1-(p-sulfophenyl)-4-[(p-sulfophenyl)azo]-2-pyrazoline-3-carboxylic acid, trisodium salt); disodium salt of 1-p-sulphophenylazo-2-naphthol-6-sulfonic acid); trisodium-2-hydroxy-1-(4-sulfonato-1-naphthylazo) naphthalene-6,8-disulfonate); disodium 4,4'-(2,4-dihydroxy-5-hydroxymethyl-3,3-phenylene bisazo)di(napthalene-1-sulfonate)); tetrasodium 4-acetamido-5-hyroxy-6-[7-sulfonato-4-(4-sulfonatophenylazo)-1-naphthylazo ]naphthalene-1,7-disulfonate); disodium 4-hydroxy-3-(4-sulfanato-1-naphythylazo) Naphthalene-1-sulfonate); trisodium 2-hydroxy-1-(4-sulfonato-1-naphthylazo) naphthalene-3,6-disulfonate); and mixtures thereof.

22. The sustained-release formulation of claim 1, wherein said compressibility augmenting agent is a surfactant included in an amount from about 0.1% to about 0.5% by weight, based on the weight of microcrystalline cellulose.

23. The sustained-release formulation of claim 1, wherein said augmented microcrystalline cellulose is wet granulated with said sustained-release carrier.

24. The sustained-release formulation of claim 1, wherein said augmented microcrystalline cellulose is wet granulated with said active agent.

25. The sustained-release formulation of claim 23, wherein said active agent, augmented microcrystalline cellulose and said sustained-release carrier are compressed into a tablet.

26. The sustained-release formulation of claim 24, wherein said active agent, augmented microcrystalline cellulose and said sustained-release carrier are compressed into a tablet.

27. The sustained-release formulation of claim 25, wherein said sustained-release carrier comprises a retardant selected from the group consisting of alkylcelluloses, acrylic and methacrylic acid polymers and copolymers, polylactides, polyglycolides, cellulose ethers, cellulose esters, polyanhydrides, polyorthoesters, polycaprolactones, polyphosphazenes, polysaccharides, proteinaceous polymers, polypeptides, polyesters, polyorthoesters, hydrophilic polymers, hydrophilic gums, waxes and wax-like materials, and mixtures thereof.

28. The sustained-release formulation of claim 26, wherein said sustained-release carrier comprises a retardant selected from the group consisting of alkylcelluloses, acrylic and methacrylic acid polymers and copolymers, polylactides, polyglycolides, cellulose ethers, cellulose esters, polyanhydrides, polyorthoesters, polycaprolactones, polyphosphazenes, polysaccharides, proteinaceous polymers, polypeptides, polyesters, polyorthoesters, hydrophilic polymers, hydrophilic gums, waxes and wax-like materials, and mixtures thereof.

29. The sustained-release formulation of claim 1, wherein said augmented microcrystalline cellulose includes a compressibility augmenting agent which inhibits interaction between adjacent cellulose surfaces via the creation the hydrophobic boundary at cellulose surfaces.

30. The sustained-release of claim 24, wherein said augmented microcrystalline cellulose and said active agent are compressed into tablets and said sustained-release carrier is applied as a coating on said tablets.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc